Author

Irene García de la filia Molina

EOSINOPHILIC GASTRITIS IN A ULCERATIVE COLITIS PATIENT TREATED WITH ADALIMUMAB
EOSINOPHILIC GASTRITIS IN A ULCERATIVE COLITIS PATIENT TREATED WITH ADALIMUMAB

Irene García de la filia Molina  et al.

EFFECTIVENESS AND SAFETY OF A SECOND-LINE RESCUE THERAPY IN HOSPITALISED PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS STEROID-REFRACTORY AFTER FAILING INFLIXIMAB OR CICLOSPORIN (REASUC STUDY)
EFFECTIVENESS AND SAFETY OF A SECOND-LINE RESCUE THERAPY IN HOSPITALISED PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS STEROID-REFRACTORY AFTER FAILING INFLIXIMAB OR CICLOSPORIN (REASUC STUDY)

Irene García de la filia Molina  et al.

LONG-TERM EXPERIENCE WITH USTEKINUMAB IN ULCERATIVE COLITIS PATIENTS: A REAL LIFE MULTICENTRE SPANISH COHORT
LONG-TERM EXPERIENCE WITH USTEKINUMAB IN ULCERATIVE COLITIS PATIENTS: A REAL LIFE MULTICENTRE SPANISH COHORT

Irene García de la filia Molina  et al.

IMPACT OF USTEKINUMAB ON EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES IN A COHORT OF PATIENTS WITH ULCERATIVE COLITIS IN REAL LIFE: THE ULISES STUDY
IMPACT OF USTEKINUMAB ON EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES IN A COHORT OF PATIENTS WITH ULCERATIVE COLITIS IN REAL LIFE: THE ULISES STUDY

Irene García de la filia Molina  et al.

REAL WORLD EVIDENCE OF USTEKINUMAB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY: THE ULISES STUDY
REAL WORLD EVIDENCE OF USTEKINUMAB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY: THE ULISES STUDY

Irene García de la filia Molina  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY
EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY

Irene García de la filia Molina  et al.

REAL-LIFE EXPERIENCE OF THE EFFICACY, SAFETY AND PHARMACOKINETIC DATA OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INACTIVE INFLAMMATORY BOWEL DISEASE PATIENTS. RESULTS FROM THE ENEIDA REGISTRY
REAL-LIFE EXPERIENCE OF THE EFFICACY, SAFETY AND PHARMACOKINETIC DATA OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INACTIVE INFLAMMATORY BOWEL DISEASE PATIENTS. RESULTS FROM THE ENEIDA REGISTRY

Irene García de la filia Molina  et al.

Item 1 - 7 / 7
1